

## Kite Pharma Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 25-Apr-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 13

Product Portfolio Drugs..... 16

[Return to Table of Contents](#)

# Kite Pharma Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Kite Pharma Inc
<b>Parent Company Name</b>	Kite Pharma Inc
<b>Website</b>	<a href="http://www.kitepharma.com/">http://www.kitepharma.com/</a>
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	9
<b>Number of Inactive Drugs</b>	1
<b>Number of Patents as Owner</b>	10
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	9
<b>Key Indications</b>	Cancer, Colorectal tumor, Lung tumor, B-cell lymphoma, Glioblastoma, Metastasis, Non-Hodgkin lymphoma, Renal cell carcinoma, Melanoma, Breast tumor, Ovary tumor, Prostate tumor
<b>Key Target-based Actions</b>	Alpha-fetoprotein inhibitor, B-lymphocyte antigen CD19 inhibitor, T cell surface glycoprotein CD28 inhibitor, Cancer testis antigen NY-ESO-1 modulator, Arginase modulator, CD27 agonist, CD45RO agonist, CD62L agonist, CD66e agonist, CD80 modulator, CTAG1 gene modulator, Cyclin-dependent kinase-4 stimulator, Epidermal growth factor agonist, FOXO3 gene modulator, MART-1 melanoma antigen stimulator, Melanocyte protein Pmel 17 modulator, Melanoma associated antigen 1 modulator, Melanoma associated antigen stimulator, Mesothelin modulator, Mesothelin stimulator, Mucin 1 stimulator, Myelin basic protein stimulator, Myelin oligodendrocyte glycoprotein stimulator, T-cell surface glycoprotein CD8 stimulator
<b>Key Technologies</b>	Biological therapeutic, T-lymphocyte, Receptor chimeric, Cell therapy, Antigen, Parenteral formulation unspecified, Systemic formulation unspecified, Polynucleotide sequence, Tumor antigen, Antibody, Antibody fragment, Antigen presentation system, Autoantigen, Cell culture technique, Immunodetection, Isolation technology, Oligonucleotide, Peptide, Vector expression, Yeast recombinant

## COMPANY PROFILE

### SUMMARY

Kite Pharma is a biotechnology company focused on the development of immunotherapeutic products to treat cancers.

### COMPANY LOCATION

In February 2015, the company entered into a lease agreement for a commercial manufacturing facility in El Segundo, CA, and also secured a lease for a clinical manufacturing facility in Santa Monica, CA. The two facilities would support the planned clinical trials of the company's product candidates, inclusive of the commercial launch and supply of the company's lead product candidate, KTE-C19, which was anticipated in 2017.

### ACQUISITIONS AND SPIN-OFFS

In March 2015, the company acquired T-Cell Factory BV, a privately held Dutch company, and renamed it as Kite Pharma EU. Kite's acquisition of TCF included an upfront payment of up to €20.0M (US \$21.0M) to TCF shareholders, licensors and employees, of which €3.8M (US \$4.0M) would be paid in Kite stock.

### FINANCIAL

In December 2014, the company was selected for addition to the NASDAQ Biotechnology Index, and it would be effective from December 22, 2014.

In November 2014, the company planned for a follow-on public offering of shares of its common stock. In December

[Return to Table of Contents](#)



2014, Kite priced the offering of 3,485,000 common stock shares at a price of US \$54 each. The underwriters were granted a 30-day option to buy up to an additional 522,750 shares of common stock. Later that month, the underwriters exercised in full their option at a price of \$54 per share. The option exercise was expected to close on January 02, 2015.

In May 2014, Kite Pharma filed a registration statement on form S-1 with the US SEC for a proposed IPO to offer their common stock shares. In June 2014, the company initiated pricing of its initial public offering of 7.5 million shares of its common stock at a price to the public of \$17 per share. The shares began trading on the NASDAQ Global Select market, under the symbol "KITE". At that time, the underwriters were granted a 30-day option to buy up to an additional 1,125,000 shares of common stock; later that month, the underwriters completely exercised their option to purchase the additional shares of the company's common stock. At that time, the total number of 8,625,000 shares was being sold in the offering and was expected to be closed on June 25, 2014.

In April 2014, the company completed a \$50 million mezzanine private financing of convertible notes.

In May 2013, Kite closed a \$20 million private placement of shares and converted \$15 million in outstanding promissory notes into shares as a part of its series A preferred stock.

In March 2011, the company raised \$15 million in from a private placement financing round.

## COMPANY FINANCIALS

### SHARE INFORMATION

<b>Close Price (USD)</b>	60.58
<b>Change (USD)</b>	-0.35 (-0.57%)
<b>Previous Close Price (USD)</b>	60.93
<b>Volume</b>	807,303
<b>52-Week High (USD)</b>	89.21
<b>52-Week Low (USD)</b>	21.00
<b>Date</b>	24-Apr-2015
<b>Exchange</b>	NASDAQ(COMPOSITE)
<b>Current Number of Shares Outstanding</b>	42,520,601
<b>Current Market Capitalization</b>	2,766,390,301
<b>EPS (Date Reported)</b>	-1.86525

[Return to Table of Contents](#)



## STOCK PERFORMANCE



## MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Capital Research Global Investors	Investment Advisor	United States	4,986,299	11.73	1,129,152	0.29	30-Jan-2015
American Funds New Economy Fund	Mutual Fund	United States	2,612,641	6.14	2,612,641	1	31-Mar-2015
American Funds SMALLCAP World Fund	Mutual Fund	Singapore	2,027,646	4.77	2,027,646	1	31-Mar-2015
Fidelity Select Biotechnology Portfolio	Mutual Fund	United States	1,115,757	2.62	0	0	28-Feb-2015
American Funds Insurance Series Global Small Capitalization	Mutual Fund	England	511,739	1.2	0	0	31-Mar-2015
Vanguard Small-Cap Index Fund	Mutual Fund	United States	496,385	1.17	276,787	1.26	31-Mar-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	484,726	1.14	274,597	1.31	31-Mar-2015
iShares NASDAQ Biotechnology ETF	Mutual Fund	United States	477,924	1.12	29,458	0.07	31-Mar-2015


[Return to Table of Contents](#)



Fidelity Growth Company Fund	Mutual Fund	United States	410,000	0.96	-800	-0	28-Feb-2015
SPDR S&P Biotech ETF	Mutual Fund	United States	363,726	0.86	363,726	1	31-Mar-2015
Vanguard Small-Cap Value Index Fund	Mutual Fund	United States	276,334	0.65	155,640	1.29	31-Mar-2015
Franklin Templeton Invest-Biotechnology Discovery	Mutual Fund	United States	214,500	0.5	-18,300	-0.08	31-Jan-2015
Fidelity Advisor Biotechnology Fund	Mutual Fund	United States	212,437	0.5	0	0	28-Feb-2015
iShares Russell 2000 ETF	Mutual Fund	United States	161,855	0.38	1,522	0.01	31-Mar-2015
JPMorgan Small Cap Growth Fund	Mutual Fund	United States	116,844	0.27	-28,378	-0.2	28-Feb-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	107,340	0.25	18,100	0.2	28-Feb-2015
Fidelity Series Growth Company Fund	Mutual Fund	United States	101,300	0.24	0	0	28-Feb-2015
Fidelity Blue Chip Growth Fund	Mutual Fund	United States	99,100	0.23	63,800	1.81	28-Feb-2015
Rydex Biotechnology Fund	Mutual Fund	United States	96,400	0.23	12,300	0.15	28-Feb-2015
Prudential Jennison Health Sciences Fund	Mutual Fund	United States	77,061	0.18	0	0	28-Feb-2015

[Return to Table of Contents](#)





	2012	2013	2014		
Sales (USD M)	0	0	0		
Operating Income (USD M)	-2.581146	-6.427347	-36.658		
Net Income (USD M)	-2.57269	-6.36553	-42.569		

[Return to Table of Contents](#)

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	0	-13.254	-13.018
2014 Q3	0	-9.101	-9.051
2014 Q2	0	-11.14	-17.89
2014 Q1	0	-3.161954	-3.698373
2013 Q4	0	-2.399347	-2.947253
2013 Q3	0	-1.506	-2.052
2013 Q2	0	-1.433	-1.734
2013 Q1	0	-1.088649	-1.061012

## BALANCE SHEET

### Assets (USD M)

	2012	2013	2014		
Cash & Short Term Investments	8.65139	22.357478	367.04		
Inventories - Total	0	0	0		
Current Assets - Total	8.844355	22.597501	368.37		
Property, Plant And Equipment - Net	0.016758	0.273641	2.093		
Other Assets - Total	0.031497	0.111266	0.29		
Total Assets	8.89261	22.982408	370.753		

### Liabilities (USD M)

	2012	2013	2014		
Accounts Payable	0.127621	0.382428	2.32		
Short Term Debt & Current Portion Of Long Term Debt	0	0	0		
Current Liabilities - Total	0.614338	1.362339	6.725		
Long Term Debt	0.25	0	0		
Other Liabilities	0.14094	0	1.328		
Total Liabilities	1.045399	1.401291	8.164		

[Return to Table of Contents](#)



## Stockholders Equity (USD M)

	2012	2013	2014		
Minority Interest	0	0	0		
Preferred Stock	0	0.020315	0		
Common Stock	0.005415	0.005528	0.042		
Treasury Stock	0	0			
Total Liabilities & Shareholders' Equity	8.89261	22.982408	370.753		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-0.74	0.66	0.84
31-Dec-2016	-1.96	-1.4	-1.4
31-Dec-2017	-1.32	-0.16	-0.16

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0	0.35	-21.9	52.44
31-Dec-2016	0	-1.74	-91.42	24.41
31-Dec-2017	0	-0.86	-66.21	107.13


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	9	1	10
Gastrointestinal disease	1	1	2
Hematological disease	1	0	1
Respiratory disease	1	0	1
Immune disorder	1	0	1
Genitourinary disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	4
Phase 1 Clinical	1
Discovery	4
Discontinued	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Patent - Exclusive Rights	0	0	2	0	2
Drug - Asset Divestment	0	0	1	0	1
Drug - CRADA	0	0	1	0	1
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	3	0	0	0	3
Drug - Development Services	0	0	1	0	1

[Return to Table of Contents](#)

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Hematological disease	1	2
Neoplasm	1	2
Immune disorder	1	2

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	1
Phase 1	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Endocrine disease	3	0	3
Gastrointestinal disease	2	0	2
Genitourinary disease	4	0	4
Andrology	2	0	2
Immune disorder	1	0	1
Neoplasm	10	0	10
Respiratory disease	4	0	4
Infectious disease	4	0	4
Gynecology and obstetrics	3	0	3
Dermatological disease	7	0	7

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### EGFRvIII chimeric antigen receptor program, Kite Pharma

<b>Drug Name</b>	EGFRvIII chimeric antigen receptor program, Kite Pharma
<b>Key Synonyms</b>	
<b>Originator Company</b>	National Cancer Institute
<b>Active Companies</b>	Kite Pharma Inc
<b>Inactive Companies</b>	National Cancer Institute
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Glioblastoma
<b>Target-based Actions</b>	Epidermal growth factor receptor modulator
<b>Other Actions</b>	Anticancer, Genetically engineered autologous cell therapy
<b>Technologies</b>	Receptor chimeric, Cell therapy, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	04-Jun-2014

### KTE-C19

<b>Drug Name</b>	KTE-C19
<b>Key Synonyms</b>	
<b>Originator Company</b>	Kite Pharma Inc
<b>Active Companies</b>	Amgen Inc, Kite Pharma Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Non-Hodgkin lymphoma, Cancer, B-cell lymphoma
<b>Target-based Actions</b>	T cell surface glycoprotein CD28 inhibitor, B-lymphocyte antigen CD19 inhibitor
<b>Other Actions</b>	Anticancer, CD3 antagonist, Immunomodulator, Genetically engineered autologous cell therapy
<b>Technologies</b>	Receptor chimeric, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	27-Mar-2015

[Return to Table of Contents](#)





### anti-NY-ESO-1 T-cell therapy (cancer), Kite Pharma

<b>Drug Name</b>	anti-NY-ESO-1 T-cell therapy (cancer), Kite Pharma
<b>Key Synonyms</b>	
<b>Originator Company</b>	National Institutes of Health
<b>Active Companies</b>	Kite Pharma Inc
<b>Inactive Companies</b>	National Institutes of Health
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Metastasis
<b>Target-based Actions</b>	Cancer testis antigen NY-ESO-1 modulator
<b>Other Actions</b>	Anticancer, Genetically engineered autologous cell therapy
<b>Technologies</b>	T-lymphocyte, Cell therapy, Systemic formulation unspecified, Biological therapeutic
<b>Last Change Date</b>	01-Jul-2014

### HPV E6/E7 targeting TCR-based T-cell therapy (cancer), Kite Pharma

<b>Drug Name</b>	HPV E6/E7 targeting TCR-based T-cell therapy (cancer), Kite Pharma
<b>Key Synonyms</b>	
<b>Originator Company</b>	National Institutes of Health
<b>Active Companies</b>	Kite Pharma Inc
<b>Inactive Companies</b>	National Institutes of Health
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Human papillomavirus E6 protein modulator, Human papillomavirus E7 protein modulator
<b>Other Actions</b>	Anticancer, Genetically engineered autologous cell therapy
<b>Technologies</b>	T-lymphocyte, Cell therapy, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	20-Feb-2015

[Return to Table of Contents](#)



## DC-Ad-GMCAIX

<b>Drug Name</b>	DC-Ad-GMCAIX
<b>Key Synonyms</b>	
<b>Originator Company</b>	University of California Los Angeles
<b>Active Companies</b>	Kite Pharma Inc
<b>Inactive Companies</b>	University of California Los Angeles
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Renal cell carcinoma
<b>Target-based Actions</b>	Carbonic anhydrase-IX modulator
<b>Other Actions</b>	Anticancer, Protein subunit vaccine, Therapeutic vaccine
<b>Technologies</b>	Tumor antigen therapeutic, Antigen, Biological therapeutic, Protein fusion, Intradermal formulation
<b>Last Change Date</b>	18-Jun-2014

## anti-SSX2 T-cell therapy (cancer), Kite Pharma

<b>Drug Name</b>	anti-SSX2 T-cell therapy (cancer), Kite Pharma
<b>Key Synonyms</b>	
<b>Originator Company</b>	National Institutes of Health
<b>Active Companies</b>	Kite Pharma Inc
<b>Inactive Companies</b>	National Institutes of Health
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Synovial sarcoma X breakpoint protein 2 inhibitor
<b>Other Actions</b>	Anticancer, Genetically engineered autologous cell therapy
<b>Technologies</b>	T-lymphocyte, Cell therapy, Biological therapeutic
<b>Last Change Date</b>	18-Feb-2015

[Return to Table of Contents](#)

### Chimeric Antigen Receptor eACTs (cancer), Kite/ Amgen

<b>Drug Name</b>	Chimeric Antigen Receptor eACTs (cancer), Kite/ Amgen
<b>Key Synonyms</b>	
<b>Originator Company</b>	Kite Pharma Inc
<b>Active Companies</b>	Kite Pharma Inc, Amgen Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer, Genetically engineered autologous cell therapy
<b>Technologies</b>	T-lymphocyte, Receptor chimeric, Biological therapeutic
<b>Last Change Date</b>	07-Jan-2015

### chimeric antigen receptor T cell therapy (cancer), Kite Pharma/ Tel Aviv Sourasky Medical Center

<b>Drug Name</b>	chimeric antigen receptor T cell therapy (cancer), Kite Pharma/ Tel Aviv Sourasky Medical Center
<b>Key Synonyms</b>	
<b>Originator Company</b>	Kite Pharma Inc
<b>Active Companies</b>	Kite Pharma Inc, Tel Aviv Sourasky Medical Center
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Genetically engineered autologous cell therapy, Anticancer
<b>Technologies</b>	T-lymphocyte, Receptor chimeric, Cell therapy, Biological therapeutic
<b>Last Change Date</b>	24-Jan-2015

[Return to Table of Contents](#)

T-cell therapy (epithelial tumors), Kite Pharma

Drug Name	T-cell therapy (epithelial tumors), Kite Pharma
Key Synonyms	
Originator Company	Kite Pharma Inc
Active Companies	Kite Pharma Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Colorectal tumor, Lung tumor
Target-based Actions	
Other Actions	Anticancer, Genetically engineered autologous cell therapy
Technologies	T-lymphocyte, Cell therapy, Biological therapeutic
Last Change Date	03-Mar-2015

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

